Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Sign up for Axios NW Arkansas
Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters
The New York Times takes a step back from the lawsuits and criminal charges against opioid manufacturers to note that McKinsey, the consulting firm, also keeps coming up in those proceedings.
The big picture: Purdue Pharma and Johnson & Johnson both hired McKinsey to boost opioid sales. McKinsey hasn't been charged or sued for any role in the crisis, but details about the company's involvement have nevertheless crept out through testimony and court filings.
Why it matters: One constant, in every lawsuit and criminal case, is that drugmakers were laser-focused on sales above all else — sometimes illegally, but sometimes just by treating the drugs like any other corporate sales project.
- Former Insys executives were recently convicted of bribing doctors to prescribe its painkiller, Subsys. But the trial also revealed a host of other, more mundane tactics designed to boost Subsys sales.
- Emails show a similar mindset at Purdue. When told that OxyContin addiction would get worse if the drug wasn't regulated as a controlled substance, former CEO Richard Sackler asked, "How substantially would it improve your sales?”
- And you hire McKinsey because of its expertise in maximizing profit, not because it knows how best to treat patients.
That sales-first mentality did not start or stop with opioids.
- Johnson & Johnson testified that it's still working with McKinsey on its other drugs, the Times notes.
- Pharmaceutical companies spend roughly $26 billion per year on marketing.
Go deeper: There are more opioid overdoses in the suburbs than ever
Editors' note: This story has been updated to reflect corrections in the New York Times story it references.